Robert A. Lenz
Insider Reports History
- Location
- Watertown, MA
- Signature
- /s/ Xi-Yong (Sean) Fu as attorney-in-fact
- All insider transactions
- Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date
Holdings reported by Robert A. Lenz:
| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Neumora Therapeutics, Inc. | Head of R&D | Common Stock | 309,092 | $516,616 | $1.67 | 18 Feb 2025 | Direct |
| Neumora Therapeutics, Inc. | Head of R&D | Stock Option (Right to Buy) | 100,000 | 13 Feb 2025 | Direct | ||
| LB PHARMACEUTICALS INC | Director | Stock Option (Right to Buy) | 20,000 | 06 Mar 2026 | Direct |
Insider Reports Filed by Robert A. Lenz
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| NBP | NovaBridge Biosciences | 18 Mar 2026 | 0 | $0 | 3 | Director | 18 Mar 2026, 21:25 |
| LBRX | LB PHARMACEUTICALS INC | 06 Mar 2026 | 1 | $0 | 4 | Director | 10 Mar 2026, 16:19 |
| LBRX | LB PHARMACEUTICALS INC | 06 Mar 2026 | 0 | $0 | 3 | Director | 10 Mar 2026, 16:16 |
| NMRA | Neumora Therapeutics, Inc. | 18 Feb 2025 | 1 | -$9,383 | 4 | Head of R&D | 20 Feb 2025, 17:12 |
| NMRA | Neumora Therapeutics, Inc. | 13 Feb 2025 | 4 | $0 | 4 | Head of R&D | 18 Feb 2025, 16:30 |
| NMRA | Neumora Therapeutics, Inc. | 09 Oct 2024 | 2 | -$208,110 | 4 | Head of R&D | 11 Oct 2024, 16:10 |
| NMRA | Neumora Therapeutics, Inc. | 17 Sep 2024 | 2 | -$492,827 | 4 | Head of R&D | 19 Sep 2024, 16:35 |
| NMRA | Neumora Therapeutics, Inc. | 12 Sep 2024 | 1 | -$376,665 | 4 | Head of R&D | 16 Sep 2024, 16:05 |
| NMRA | Neumora Therapeutics, Inc. | 14 Feb 2024 | 2 | $0 | 4 | Head of R&D | 16 Feb 2024, 16:13 |
| NMRA | Neumora Therapeutics, Inc. | 14 Sep 2023 | 2 | $0 | 4 | Head of R&D | 18 Sep 2023, 17:58 |
| NMRA | Neumora Therapeutics, Inc. | 14 Sep 2023 | 0 | $0 | 3 | Head of R&D | 14 Sep 2023, 19:06 |